Patents Assigned to Bioscience, Inc.
  • Anti-IL31 antibodies for veterinary use
    Patent number: 10150810
    Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: December 11, 2018
    Assignee: Kindred Biosciences, Inc.
    Inventors: Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
  • Peptides having anti-inflammatory properties
    Patent number: 10149886
    Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 11, 2018
    Assignee: Riptide Bioscience, Inc.
    Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
  • Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
    Patent number: 10149856
    Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: December 11, 2018
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
  • PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES
    Publication number: 20180344817
    Abstract: The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome. The invention provides a general method for treating nucleotide repeat expansion disorders and engineered nucleases suitable for practicing the method. The invention further provides vectors and techniques for delivering engineered nucleases to patient cells.
    Type: Application
    Filed: May 2, 2016
    Publication date: December 6, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Victor Bartsevich, Derek Jantz
  • CELL CULTURE INCUBATORS WITH INTEGRATED IMAGING SYSTEMS
    Publication number: 20180346868
    Abstract: Aspects relate to automated cell culture incubators comprising imaging systems, e.g., holographic or phase-contrast imagers, configured for imaging said cells within the incubators.
    Type: Application
    Filed: March 31, 2016
    Publication date: December 6, 2018
    Applicant: Thrive Bioscience ,Inc.
    Inventor: Alan BLANCHARD
  • METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES
    Publication number: 20180344702
    Abstract: The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.
    Type: Application
    Filed: February 21, 2018
    Publication date: December 6, 2018
    Applicants: Aptose Biosciences Inc., CrystalGenomics, Inc.
    Inventors: William G. RICE, Joong Myung CHO, Yongrae HONG
  • METHOD OF MANUFACTURING A PROTEIN BY PERFUSION IN MEDIA WITH A LOW AMINO ACID CONCENTRATION
    Publication number: 20180346550
    Abstract: Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process.
    Type: Application
    Filed: August 13, 2018
    Publication date: December 6, 2018
    Applicant: Coherus Biosciences, Inc.
    Inventors: Ela PUCHACZ, James Russell GROVE
  • Methods of using interleukin-10 for treating diseases and disorders
    Patent number: 10143726
    Abstract: Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: December 4, 2018
    Assignee: Armo Biosciences, Inc.
    Inventor: Martin Oft
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10143699
    Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 4, 2018
    Assignee: Calithera Biosciences, Inc.
    Inventors: Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
  • RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
    Publication number: 20180340160
    Abstract: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 29, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Derek Jantz
  • Inoculation by applying nanosecond pulsed electric fields to a biopsy and reintroducing the treated biopsy to the subject
    Patent number: 10137152
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: November 27, 2018
    Assignee: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Substituted triazoles and methods relating thereto
    Patent number: 10138214
    Abstract: Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R1, R2, R3 and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: November 27, 2018
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
  • Engineered nucleic-acid targeting nucleic acids
    Patent number: 10138472
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 27, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
    Patent number: 10130695
    Abstract: Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: November 20, 2018
    Assignees: Vedanta Biosciences, Inc., RIKEN
    Inventors: Kenya Honda, Bernat Olle, Koji Atarashi, Takeshi Tanoue, Hiroshi Ohno, Shinji Fukuda, Koji Hase
  • PEPTIDE CONSTRUCTS AND ASSAY SYSTEMS
    Publication number: 20180328936
    Abstract: The present invention provides methods for constructing peptide construct sets and methods of use of these peptide construct sets in assay systems for peptide analysis, and in particular for use in high throughput peptide analysis. The methods allow for analysis of large sets of peptide constructs in a cost-effective manner, employing molecular biological techniques that are both robust and easily parallelized. Thus, the methods allow for the construction of peptide construct sets encompassing, e.g., the human proteome.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 15, 2018
    Applicant: Prognosys Biosciences, Inc.
    Inventors: Igor A. Kozlov, Mark S. Chee, Petr Capek, David A. Routenberg
  • Engineered nucleic-acid targeting nucleic acids
    Patent number: 10125354
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Compositions and methods of nucleic acid-targeting nucleic acids
    Patent number: 10125361
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 13, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Reagent cartridge and methods for detection of cells
    Patent number: 10125386
    Abstract: An apparatus includes a housing and an actuator. The housing, which defines a reagent volume that can receive a reagent container, can be removably coupled to a reaction chamber. The housing includes a puncturer that defines a transfer pathway in fluid communication with the reagent volume. A delivery portion of the housing defines a delivery pathway between the transfer pathway and the reaction chamber when the housing is coupled to the reaction chamber. The actuator has a plunger portion disposed within the reagent volume. An engagement portion of the actuator can be manipulated to move the plunger portion within the reagent volume to deform the reagent container. The puncturer can pierce a frangible portion of the reagent container to convey a reagent from the reagent container into the reaction chamber via the transfer pathway and/or the delivery pathway.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: November 13, 2018
    Assignee: GeneWeave Biosciences, Inc.
    Inventors: Nikol De Forest, Werner Frei, Diego Rey, Shaunak Roy, Soni Shukla, Ryan C. Griswold, Kenneth G. Olson, Bruce J. Richardson, Victor H. Yee
  • Anti-HER2 antibody-maytansine conjugates and methods of use thereof
    Patent number: 10124070
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • Guidewire stylette
    Patent number: D835777
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: December 11, 2018
    Assignee: Arkis BioSciences Inc.
    Inventors: Chad Eric Seaver, James Chris Arnott, James Alexander Killeffer, Quentin T. Aten